We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.31 | 0.48% | 65.51 | 65.43 | 65.89 | 65.8892 | 64.97 | 65.32 | 7,232,521 | 00:55:07 |
From May 2019 to May 2024
Combined sales of Type 2 diabetes treatments Januvia and Janumet declined 12%. "Merck Revenue and Profit Falls -- Update," published at 12:38 p.m. EST, incorrectly stated that Januvia sales alone declined 12% in the eighth paragraph. The error also appeared in an earlier version of the story published at 7:51 a.m. EST
(END) Dow Jones Newswires
February 03, 2016 15:54 ET (20:54 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
